AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🔴 AIM ImmunoTech is trading 5% down today with no clear company-specific catalyst identified
AIM ImmunoTech is trading 5.06% down now at $0.21 after no clear company-specific catalyst was identified for September 18, 2026. - CEO Thomas Equels...
🔴 AIM ImmunoTech is trading 5% down in pre-market as no clear company-specific catalyst was identified
AIM ImmunoTech is trading 5.15% down at $0.21 after no clear company-specific catalyst was identified for September 18, 2026. - Recent disclosures include a...
AIM ImmunoTech Converts Approximately $400,000 of Debt into Common Stock
AIM ImmunoTech Inc. announced it has entered into exchange agreements to convert a portion of an outstanding promissory note into equity. The company settled...
🔴 AIM ImmunoTech is trading 5.5% down in pre-market amid broader risk-off conditions
AIM ImmunoTech is trading 5.5% down at $0.21 in pre-market as broader risk-off conditions, including weaker U.S. futures and rate concerns, appear to be the...
🔴 AIM ImmunoTech is trading 7.8% down in pre-market with no clear company-specific catalyst
AIM ImmunoTech is trading 7.8% down at $0.21 after no clear company-specific catalyst emerged overnight. - The latest official release, dated September 9,...
🔴 AIM ImmunoTech is trading 6.35% down today amid broader market weakness
AIM ImmunoTech is trading 6.35% down at $0.22, with no clear company-specific catalyst identified for the September 10, 2026 decline. - Latest highlighted...
🔴 AIM ImmunoTech is trading 5.45% down in pre-market with no clear company-specific catalyst
AIM ImmunoTech is trading at $0.22 (-5.45%) in pre-market with no clear company-specific catalyst for the September 10, 2026 decline. - On September 9, the...
AIM ImmunoTech Satisfies Promissory Note Through a $1.22M Debt-for-Equity Exchange
AIM ImmunoTech Inc. has fully satisfied a promissory note held by Streeterville Capital, LLC by converting the outstanding debt into common stock. The company...
AIM ImmunoTech Locks Down 15-Year European Patent for Long COVID Drug — But Can a $7 Million Company Turn Paper Protection Into Real Revenue?
Shares of AIM ImmunoTech jumped 10.8% to $0.26 after the micro-cap biotech announced it secured patent protection across Europe and the United Kingdom for its...
🟢 AIM ImmunoTech is trading 10.78% up today after European and UK patent protection through 2041
AIM ImmunoTech is trading 10.78% up now at $0.26 after securing European and United Kingdom patent protection for Ampligen’s Long COVID use through June...
🟢 AIM ImmunoTech is trading 8.35% up today after European Ampligen patent protection through 2041
AIM ImmunoTech is trading at $0.25 (+8.35%) after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment through June...
🟢 AIM ImmunoTech is trading 7.29% up in pre-market after European Long COVID patent protection through 2041
AIM ImmunoTech is trading 7.29% up at $0.25 in pre-market after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment...
AIM ImmunoTech Secures European Ampligen Patent, Protecting Long COVID Treatment Until 2041
AIM ImmunoTech secured patent protection for its drug Ampligen (rintatolimod) across major European markets and the United Kingdom. This intellectual property...
🔴 AIM ImmunoTech is trading 7.16% down in pre-market
AIM ImmunoTech is trading 7.16% down now at $0.22, with no fresh negative announcement, earnings surprise, or other clear catalyst identified for September...
🟢 AIM ImmunoTech is trading 5.8% up today after announcing broad Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 5.8% up now at $0.24 after announcing a broad U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment. - The...
🟢 AIM ImmunoTech is trading 17.52% up in pre-market after broad U.S. patent covering Ampligen and pembrolizumab
AIM ImmunoTech is trading at $0.27, up 17.52% in pre-market trading on September 1, 2026, after announcing a broad U.S. patent for Ampligen combined with...
🔴 AIM ImmunoTech is trading 10.87% down today after patent-driven interest reversed intraday
AIM ImmunoTech is trading 10.87% down at $0.23 after an intraday reversal from initial buying sparked by its August 31, 2026, announcement of a broad U.S....
🔴 AIM ImmunoTech is trading 6.4% down today after intraday reversal
AIM ImmunoTech is trading at $0.24 (-6.42%) after an intraday reversal following initial buying on its patent announcement. - The company announced a broad...
AIM ImmunoTech's New Cancer Patent Sparks a 34% Rally — But Can a Sub-$10 Million Company Cash In on a $32 Billion Drug Market?
Shares of AIM ImmunoTech surged 34.3% to $0.35 on an otherwise red-tape Monday after the company announced the U.S. Patent and Trademark Office granted it...
🟢 AIM ImmunoTech is trading 34.29% up today after USPTO grants Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 34.29% up now at $0.35 after announcing on August 31, 2026, that the USPTO granted a patent covering Ampligen combined with...